Mirum Pharmaceuticals, Inc. 8-K

What Happened

• Mirum Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 15, 2026 (record date April 20, 2026; 60,977,841 shares outstanding). Stockholders elected three Class I directors — Lon Cardon, Ph.D., William Fairey, and Timothy Walbert — each to serve until the 2029 annual meeting. The company’s stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 and approved, on an advisory basis, the compensation of the named executive officers.

Key Details

• Director votes:
  • Lon Cardon: 39,587,327 For; 6,827,214 Withheld; 3,614,839 broker non-votes.
  • William Fairey: 40,266,848 For; 6,147,693 Withheld; 3,614,839 broker non-votes.
  • Timothy Walbert: 32,329,718 For; 14,084,823 Withheld; 3,614,839 broker non-votes.
• Auditor ratification: Ernst & Young LLP approved — 49,993,514 For; 5,674 Against; 30,192 Abstentions.
• Advisory vote on executive compensation: Approved — 44,534,575 For; 1,866,719 Against; 13,247 Abstentions; 3,614,839 broker non-votes.
• Elected directors will serve until the 2029 annual meeting or until successors are elected and qualified.

Why It Matters

• Board continuity and oversight: Election of the three Class I directors secures governance continuity through 2029, which can influence strategic direction and oversight of management.
• Financial reporting and audit: Ratifying Ernst & Young LLP confirms the auditor responsible for 2026 financial statements and related controls — an important factor for confidence in financial reporting.
• Shareholder approval of pay: The advisory "say-on-pay" vote was approved, indicating majority shareholder support for executive compensation disclosed in the proxy (note: the advisory vote is non-binding).
• For investors, these outcomes signal shareholder positions on governance, audit oversight, and compensation policy as reflected in the official 8-K filing.